Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
Immutep
Immutep is a global biotechnology company developing immunotherapeutic products for the treatment of cancer and autoimmune diseases.
Sector
Subsector
Location
total rounds
total raised
Virometix
Virometix develops vaccines and immunotherapeutic drugs for infectious and chronic diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
ImmuneSensor Therapeutics
ImmuneSensor Therapeutics is a biotech company developing innovative medicines for cancer and autoimmune diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Soligenix
Soligenix is a biotechnology company focused on treating rare diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds7
Number of Funding Rounds
Money Raised
Their latest funding was raised on 04.10.2023. Their latest investor Zoic Capital. Their latest round Grant
BLUE KNIGHT
BARDA and JLABS launched BLUE KNIGHT, a joint initiative for biomedical research.
Sector
Subsector
count Of Investments
Medical CBRN Defense Consortium
The Medical CBRN Defense Consortium (MCDC) partners with the US government to develop advanced medical solutions for military personnel.
Sector
Subsector
Keywords
Location
count Of Investments
US Army
The U.S. Army offers a wide range of career opportunities and training programs for individuals interested in joining the military.
Sector
Subsector
Keywords
count Of Investments
count Of Exists
Co-Investors
Investors8
Number of lead investors
Number of investors
Zoic Capital
Zoic Capital is a venture capital firm focused on early-stage healthcare innovations.
Sector
Subsector
Location
count Of Investments
Neal Mody
I’m obsessed with building great companies and focus on those life sciences that will affect humanity. Early in my career, I was fortunate enough to help scale Ambature, a materials science company in the field of superconductivity. When I started Ambature, I didn’t have any experience in materials science; nevertheless, I operated under the belief that the inventor’s idea was right. Fast forward a few years, by the time I left my role, we created over 200 patents with more than 3,700 unique claims, accounting for more than half patents in the field of superconductivity. After I left Ambature, I wanted to make a more significant impact in life sciences, and ultimately on humanity. Being driven by this social mission, I thought about starting a few companies simultaneously; however, after some back and forth, I ultimately concluded that starting a fund would better allow me to scale my efforts. Through Zoic Capital, my team and I help our portfolio companies and investors: ► Develop large scale inclusive IP development strategy ► Help connect and codevelop deals with potential strategic acquirers We are currently the only US-based venture firm focused solely on investing in the seed stage of Medtech, we go through a rigorous vetting process with each investment opportunity to ensure that: 1. their technological developments represent at least a 10X improvement in the standard of care 2. their technology relies upon scientific mechanisms which are fully supported by published literature, independent trials, and personal observation 3. in most cases, they have unique hardware and IP coupled with unique software 4. the leadership team has the necessary combination of vision and experience to create a transformational company 5. has an initial regulatory approval on a short timeline, typically two to four years If you want to learn more about Zoic, the types of companies we invest in, or if you’d like to talk about the market and feature on my podcast, feel free to get in touch with me via email: [email protected] If you know of an interesting deal for Zoic to look at, feel free to get in touch with my team here: [email protected]
current job
BLUE KNIGHT
BARDA and JLABS launched BLUE KNIGHT, a joint initiative for biomedical research.
Sector
Subsector
count Of Investments
National Institute of Allergy and Infectious Diseases
NIAID conducts research to prevent and treat infectious and allergic diseases.
Sector
Subsector
Location
count Of Investments
count Of Exists
People
Founders2
Steven Reed
Steve Reed founded Immune Design Corp. in 2008 and served as the Chief Executive Officer through May 2011. He is the founder, President and Chief Scientific Officer of the Infectious Disease Research Institute. He co-founded Corixa Corporation in 1994, where he served as Chief Scientific Officer. In 2005 he founded Dharma Therapeutics Inc., a Seattle biotech developing transdermal delivery systems. His academic appointments include Adjunct Professor of Medicine at Cornell University Medical College in New York and Research Professor of Pathobiology at the University of Washington. He serves on several editorial review committees, has served as a member of the Tropical Medicine Review Board of the National Institutes of Health and is a member of the Vaccine Development Steering Committee of the World Health Organization. Dr. Reed’s research interests have focused on the immunology of intracellular infections, and on the development of adjuvants, vaccines and diagnostics for both cancer and infectious diseases. He has more than 210 published original articles, several book chapters, and holds 101 issued patents for diagnostics, vaccines, and therapeutics for infectious diseases and cancer.
current job
organization founded
Steven Reed